Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Salgado

Showing results (261-270 of 277) with videos related to

Pageof 28
Sort By:
Cancer Cell|October 29, 2021
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinomaLewis Au, Emine Hatipoglu, Marc Robert de Massy, et al.
Nature Cancer|August 18, 2020
The T cell differentiation landscape is shaped by tumour mutations in lung cancerEhsan Ghorani, James L Reading, Jake Y Henry, et al.
Nature Communications|September 27, 2016
Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltrationMarcel Smid, F Germán Rodríguez-González, Anieta M Sieuwerts, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)Sam Sater, Carlo B Bifulco, Jaime Rodriguez-Canales, et al.
Nature|April 12, 2023
The evolution of non-small cell lung cancer metastases in TRACERxMaise Al Bakir, Ariana Huebner, Carlos Martínez-Ruiz, et al.
NPJ Breast Cancer|December 2, 2021
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working GroupKhalid El Bairi, Harry R Haynes, Elizabeth Blackley, et al.
NPJ Breast Cancer|May 16, 2020
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupMohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, et al.
The Journal of Pathology|March 5, 2020
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practicePaula I Gonzalez-Ericsson, Elisabeth S Stovgaard, Luz F Sua, et al.
Nature|July 4, 2024
Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERxAlexander M Frankell, Michelle Dietzen, Maise Al Bakir, et al.
Nature|April 12, 2023
The evolution of lung cancer and impact of subclonal selection in TRACERxAlexander M Frankell, Michelle Dietzen, Maise Al Bakir, et al.
Pageof 28

Showing results (261-270 of 277) with videos related to

Sort By:
Pageof 28
Cancer Cell|October 29, 2021
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinomaLewis Au, Emine Hatipoglu, Marc Robert de Massy, et al.
Nature Cancer|August 18, 2020
The T cell differentiation landscape is shaped by tumour mutations in lung cancerEhsan Ghorani, James L Reading, Jake Y Henry, et al.
Nature Communications|September 27, 2016
Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltrationMarcel Smid, F Germán Rodríguez-González, Anieta M Sieuwerts, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)Sam Sater, Carlo B Bifulco, Jaime Rodriguez-Canales, et al.
Nature|April 12, 2023
The evolution of non-small cell lung cancer metastases in TRACERxMaise Al Bakir, Ariana Huebner, Carlos Martínez-Ruiz, et al.
NPJ Breast Cancer|December 2, 2021
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working GroupKhalid El Bairi, Harry R Haynes, Elizabeth Blackley, et al.
NPJ Breast Cancer|May 16, 2020
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupMohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, et al.
The Journal of Pathology|March 5, 2020
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practicePaula I Gonzalez-Ericsson, Elisabeth S Stovgaard, Luz F Sua, et al.
Nature|July 4, 2024
Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERxAlexander M Frankell, Michelle Dietzen, Maise Al Bakir, et al.
Nature|April 12, 2023
The evolution of lung cancer and impact of subclonal selection in TRACERxAlexander M Frankell, Michelle Dietzen, Maise Al Bakir, et al.
Pageof 28